

RPG – April Q&A

Welcome!

Trusts Represented today include:

North Bristol, Oxford University Hospitals, Cambridge, Ayrshire, Fife,
Norfolk, Hertfordshire, Manchester, Reading, Liverpool, Guys,

April – Q&A Themes

- **Supply issues**

- 25mg Vanquoral – OOS till May
 - Dose adjustment/brand switches
- Trisodium citrate 30% - seems resolved
- Basiliximab QA product recall
- Calcichew – may be a cost saving if using Adcal
- Urocit K
- Oxycodone Liquid – high strength (10mg/ml)/immediate release available. Unlicensed available but v pricey. Risks with oramorph but could consider v low doses. ?
Resolution June

- New (Ascot) tiopronin available

April – Q&A Themes

• Renal 1

- Switching Iron preps to Monofer – anaphylaxis risk (related to free iron content. Can be managed with slower rate)
- Leicester Hosp kidney videos – available on YouTube/NKF
- Acute hyperkalaemia treatment – calcium gluconate rate clarified. Suggestion of 30ml over 5-10mins as per cardiac arrest advice (differs from Medusa). Flowchart inc Lokelma use may include primary care in future
- Renal pharmacy tech job description
- Cobalamin C deficiency
- IV Magnesium in CKD – lower doses used
- Venofer chart in non HD
- Alternatives to alfacalcidol for hypocalcaemia
- Nephrotrans formulary applications

April – Q&A Themes

- **Renal 2**

- Debranding of Monofer
- MMF dosing in vasculitis
- National Hep B PGD
- Sodium thiosulphate for calciphylaxis
- Pentrox for procedures
- Apixaban for renal vein thrombosis – less appetite for using apix in acute thrombosis (different if chronic).
Warfarin/LMWH remains preference. Some data in US showing safety of apix over warfarin. May be a place for Edox (not in GFR<15). KP in Manchester has experience/info
- Lokelma down NG/NJ tubes
- Kinpeygo availability in UK?

April – Q&A Themes

- **RRT**

- Hair loss with LMWH – using fondaparinux 2.5mg at start of HD
- Roxadustat in HD
- Carnitine for cramps
- Citrate anticoagulation
- Desferrioxamine in HD
- Bispecific antibody therapy for myeloma (not answered)
- SGLT2i's in ESRF. May be suitable to continue taking when reaches ESRF (started pre CKD5d)
- B4 NA drug administration – ok to give PO but not IV. Clinical Support Workers using line locks/prime lines. Experience at Guys, Manchester, Liverpool
- Enoxaparin -> dalteparin for circuits

April – Q&A Themes

- **Transplant**

- Enhanced recovery post transplant
- Brand switch Advagraf -> Dailiport
- Patient alert cards – some available at NKF/trust specific
- Concomitant sirolimus/tacrolimus for kidney/liver transplant
- Alexion pre-approval scheme for eculizumab

Updates

- Membranous GN - NHSE Commissioning
 - <https://www.england.nhs.uk/publication/clinical-commissioning-policy-rituximab-for-idiopathic-membranous-nephropathy/>
- EMPA KIDNEY
 - <https://www.nejm.org/doi/full/10.1056/NEJMoa2204233>
- STOP ACE
 - <https://www.nejm.org/doi/pdf/10.1056/NEJMoa2210639>
- Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis
 - Technology appraisal guidance [TA825]Published: 21 September 2022

Updates

- Marabivir for treating refractory cytomegalovirus infection after transplant
 - Technology appraisal guidance [TA860] Published 18 January 2023
- Finerenone for treating chronic kidney disease in people with type 2 diabetes [ID3773]
 - In development [GID-TA10820]Published: 23 March 2023
 - Chat within ICBs around traffic light status. ICB preferring amber, secondary care asking for green. Concern that applicable patients may not be under either renal/endocrinology, inequitable. Or will primary care referrals -> secondary care will increase. NICE TA vague around secondary care use

2023 – On the Horizon

- Difelikefalin for treating pruritus in people having haemodialysis [ID3890]
 - In development [GID-TA10793]Expected publication date: 26 April 2023
- Voclosporin with immunosuppressives for treating lupus nephritis [ID3962]
 - In development [GID-TA10878]Expected publication date: 26 April 2023

April Q&A: New Q

- Salford – swollen legs with tac (for resolving nephrotic syndrome) any experience?
 - Only been seen in untreated nephrotic syndrome .
 - Data suggests 20-30% incidence? Seems high rate, unclear confidence

April Q&A: New Q

- Guys – Request from London Kidney Network for guidelines on Imlifidase. Recommendation to push for national renal guideline.
 - Interest from some units to be part of national working group
 - Hayley to liaise with Imperial team to facilitate
 - Sara/Dane working on guidelines

April Q&A: New Q

- Hertfordshire – there is some advice around dosing of remdesivir and paxlovid in CKD 4&5 for Covid - look at UKRPG landing page for what Wales are doing at the moment (different from Liverpool website).Wales not restricted by blueteq/NHSE.
- RDD should be updated today

April Q&A: New Q

- Manchester – UKKA guideline committee have a survey around future service development. Members to please complete

April Q&A: New Q

- Liverpool – looking at a guideline to promote patiromer over lokelma in lower potassiums due to lower cost (~30K saving?)
 - Is there any progress with using patiromer at lower potassium?
 - Salford looking at this
 - Discussion around cost of keeping both on wards/risk of dose confusion/already lengthy guidelines

April Q&A: New Q



April Q&A - Close

REMINDER: WhatsApp Q&A platform – 70+ participants; Very useful real time forum for clinical Q's – please consider joining.

Thank you for attending.

Next Q&A: Tuesday 9th May @ 1pm